Last reviewed · How we verify

Extended course macrolide — Competitive Intelligence Brief

Extended course macrolide (Extended course macrolide) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Macrolide antibiotic (anti-inflammatory/immunomodulatory use). Area: Respiratory/Pulmonology.

phase 3 Macrolide antibiotic (anti-inflammatory/immunomodulatory use) Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Extended course macrolide (Extended course macrolide) — UMC Utrecht. Extended course macrolide antibiotics reduce airway inflammation and modulate immune responses in chronic respiratory conditions through anti-inflammatory and immunomodulatory effects.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Extended course macrolide TARGET Extended course macrolide UMC Utrecht phase 3 Macrolide antibiotic (anti-inflammatory/immunomodulatory use)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Macrolide antibiotic (anti-inflammatory/immunomodulatory use) class)

  1. UMC Utrecht · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Extended course macrolide — Competitive Intelligence Brief. https://druglandscape.com/ci/extended-course-macrolide. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: